Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marizyme Inc (OP: MRZM )

0.0183 -0.0167 (-47.71%)
Streaming Delayed Price Updated: 2:45 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 774
Open 0.0183
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0350
Today's Range 0.0183 - 0.0183
52wk Range 0.0313 - 0.1900
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft
JUPITER, FL - (NewMediaWire) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft® will no longer require refrigerated storage and will be able to be... 
Via TheNewswire.com
Topics Economy
Exposures Product Safety Supply Chain

Performance

YTD
-85.37%
-85.37%
1 Month
-49.17%
-49.17%
3 Month
-42.81%
-42.81%
6 Month
-77.13%
-77.13%
1 Year
-90.37%
-90.37%

More News

Read More
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
Via NewMediaWire
Exposures Product Safety
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
Via TheNewswire.com
Exposures Product Safety
Marizyme CEO Delivers Business Update
Via NewMediaWire
Exposures Product Safety
InvestmentPitch Media Video Features Marizyme's CEO David Barthel Discussing Receipt of FDA Clearance for its Flagship DuraGraft Medical Device
Via ACCESSWIRE
The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News
Via ACCESSWIRE
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft
Via NewMediaWire
Exposures Product Safety
Marizyme (OTCQB: MRZM) Announces IP Developments for DuraGraft and Its Pipeline Products
Via Spotlight Growth
Topics Intellectual Property
Exposures Intellectual Property
Marizyme Announces IP Developments for DuraGraft and Its Pipeline Products
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Marizyme (OTCQB: MRZM) CEO Delivers Business Update
Via Spotlight Growth
Exposures Product Safety
Marizyme CEO Delivers Business Update
Via NewMediaWire
Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing
Via NewMediaWire
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
Via NewMediaWire
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.